Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) Population
The ATBC study was a randomized, double-blind, placebo-controlled, primary prevention trial
to determine whether daily supplementation with a-tocopherol, (Beta)-carotene, or both would
reduce the incidence of lung or other cancers among male smokers. Between 1985 and 1988,
29,133 men ages 50 to 69 years, who smoked at least five cigarettes per day, were recruited
from southwestern Finland. Participants were randomly assigned to receive either
a-tocopherol as dl-a-tocopheryl acetate (50 mg/day), (Beta)-carotene as
all-trans-(Beta)-carotene (20 mg/day), both supplements, or placebo capsules for 5-8 years
(median 6.1 years) through April 30, 1993. Post-intervention follow-up has continued
through the Finnish Cancer Registry and other national registries, and epidemiological
analyses continue to be conducted.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Incidence of and mortality from lung cancer during intervention (ended April 1993) and post-intervention.
Demetrius A Albanes, M.D.
National Cancer Institute (NCI)
United States: Federal Government